Cytomedix Taking the Science of Wound Repair ...and Using It to Treat Wounds
About UsAutologelPatientsProfessionalsInvestorsContact Info

Investors
Press Releases  

All Cytomedix SEC Filings

Stock Info

Nominating and Corporate
    Governance Committee Charter  

Audit Committee Charter

Compensation Committee Charter

Code of Conduct and Ethics

Investor Communications

Research

Home


Additional Information:

    9-9-04 Saris Summary Judgment Ruling 
    7-26-04 Zagel Summary Judgment Ruling 
    3-23-04 Zagel Claim Construction Ruling 


Press Releases

New research reports for GTF (AMEX)
 
2008 Jun 12 AMEX:GTF Cytomedix Unveils Clinical Plans for the Development of Anti-Inflammatory Peptides
2008 Jun 09 AMEX:GTF Cytomedix Announces Transition of Leadership Martin Rosendale Appointed CEO
2008 May 14 AMEX:GTF Cytomedix Joins The Acute Long Term Hospital Association (ALTHA) as an Allied Member
2008 May 05 AMEX:GTF Cytomedix Gains Access To U.S. Government Medical Facilities By Adding The AutoloGel™ System To The Federal Supply Schedule
2008 Apr 22 AMEX:GTF Cytomedix Provides Update on Efforts to Secure Medicare Reimbursement for Its AutoloGel™ System
2008 Apr 10 AMEX:GTF Cytomedix to Exhibit at the 21ST Annaul Symposium On Advanced Wound Care (SAWC) April 24-27, 2008
2008 Mar 19 AMEX:GTF Centers For Medicare And Medicaid Services (CMS) Reaches Final Coverage Decision on PRP GEL
2008 Mar 17 AMEX:GTF Cytomedix Appoints Martin P. Rosendale Executive Vice President and Chief Operating Officer
2008 Feb 12 AMEX:GTF The Kon-Lin Letter Initiates New Coverage of Cytomedix In Its February 2008 Issue With Initial Target of $4.50-$5.00 and Ultimate Target of $7-$9
2008 Jan 30 AMEX:GTF Cytomedix Submits Comments in Response to CMS’ Proposed National Coverage Decision
2007 Dec 21 AMEX:GTF Cytomedix Announces That CMS Preliminary Affirms Non-Coverage of PRP Gel
2007 Dec 04 AMEX:GTF Cytomedix Files Registration Statement
2007 Nov 07 AMEX:GTF Cytomedix To Restate Previously Issued Financial
Statements For Stock-Option Related Compensation
2007 Oct 16 AMEX:GTF Cytomedix Licenses Technology To Smith & Nephew
2007 Oct 12 AMEX:GTF Cytomedix Issues Warrant Call
2007 Oct 08 AMEX:GTF Cytomedix Submits Cost Effectiveness Study for AutoloGel™ to CMS
2007 Aug 23 AMEX:GTF Cytomedix Announces Its Outside Patent Counsel Agrees to Take Equity Stake in the Company
2006 Oct 09 AMEX:GTF Cytomedix Appoints David A. Hotchkiss as Vice President for Sales and Marketing
2006 Aug 23 AMEX:GTF Cytomedix Autologel™ Clinical Trial Presentation Receives Top Award at APMA Annual Meeting
2006 Aug 09 AMEX:GTF Cytomedix Announces Second Quarter 2006 Financial Results
2006 Aug 02 AMEX:GTF Cytomedix Issues Warrant Call
2006 July 05 AMEX:GTF Cytomedix Joins New Russell Microcap Index
2006 Jun 28 AMEX:GTF Cytomedix Announces Publication of the Autologel Diabetic Foot Ulcer Prospective Trial
2006 May 22 AMEX:GTF Cytomedix Licenses Patents To BIOMET For $2.6 Million
2006 May 01 AMEX:GTF Cytomedix To Receive $2.2 Million From Existing Warrantholders
2006 Jan 24 AMEX:GTF CYTOMEDIX ANNOUNCES AVAILABILITY OF RESEARCH REPORT ON COMPANY

 
AutoloGel System - for preperation of Platelet Rich Plasma Gel      
Back to top  

[HOME]   [ABOUT US]   [AUTOLOGEL]   [PATIENTS]   [PROFESSIONALS]   [INVESTORS]   [CONTACT INFO]